New treatment options for lung adenocarcinoma - In view of molecular background

Pathology and Oncology Research

Volumn 20, Issue 1, 2014, Pages 11-25

  Bittner, Nora ^a   Ostoros, Gyula ^b   Géczi, Lajos ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b National Institute for TB and Pulmonology   (Hungary)

Author keywords

Adenocarcinoma; EGFR mutation; EML 4 ALK; KRAS; Monoclonal antibodies; Non Small Cell Lung Cancer (NSCLC); Signal transduction pathway; Targeted therapies; Tyrosine kinase inhibitors; VEGFR

Indexed keywords

AFATINIB; AFLIBERCEPT; ANAPLASTIC LYMPHOMA KINASE; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CANERTINIB; CEDIRANIB; CETUXIMAB; CRIZOTINIB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMMUNOMODULATING AGENT; LINIFANIB; METMAB; MOTESANIB; NERATINIB; NINTEDANIB; ONARTUZUMAB; PAZOPANIB; PELITINIB; PF 0299804; PROTEIN RET; RAMUCIRUMAB; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ADVANCED CANCER; AKT GENE; APOPTOSIS; BRAF GENE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EXPOSURE; DRUG MECHANISM; EGFR GENE; EML 4 ALK FUSION GENE; FUSION GENE; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAP2K1 GENE; MET GENE; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE K RAS; ONCOGENE RET; PIK3CA GENE; PROGRESSION FREE SURVIVAL; REVIEW; ROS1 GENE; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE;

EID: 84896052573     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9719-9     Document Type: Review

References (79)

1. Travis WD, Brambilla E et al (2011) International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thoracic Oncol 6:2244-2285
2. Mino-Kenudson M et al (2010) A novel, high sensitive antibody allows for the routine detection of ALK - rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16:1561-1571
3. Shiller JH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2:92-98
4. NSCLC Meta-Analysis Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomised controlled trials. J Clin Oncol 28:4617-4625
5. Azolli CG (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 36:6251-6266
6. Ettinger DS (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 7:740-801
7. Paz-Ares L (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced nonsquamosus non-small cell lung cancer (PARAMOUNT): a double - blind, phase 3, randomised controlled trial. Lancet Oncol 3:247-255
8. Paz-Ares L, PPARAMOUNT (2012) Final overall survival (OS) result of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediatly following induction treatment with pem plus cisplatin (cis) for advanced nonsquamosus (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 30:(Suppl; abstr LBA7507)
9. Pennel NA (2009) Combined inhibition of the VEGFR and EGFR signalling pathways in the treatment of NSCLC. Oncologist 14:399-411
10. Oxanard GR, Binder A (2013) New targetable oncogenes in Non-small-cell lung cancer. J Clin Oncol 31:1097-1104
11. Gaughan EM (2011) Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 3:113-125
12. Hynes NE, Lane H (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354 (Pubitemid 40637826)
13. Gazdar AF (2009) Acitvating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical responses to EGFR tyrosine kinase inhibitors. Oncogene 28:24-31
14. Lee YJ et al (2011) Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer 72:9-15
15. Reinersman JM et al (2011) Frequency of EGFR and KRAS mutations in lung adenocarcinoma in African Americans. J Thorac Oncol 6:28-31
16. Patrick JR, Thomas ES (2013) KRAS mutation: should We test for it, and does it matter? J Clin Oncol 31:1112-1121
17. Guan JL et al (2013) KRAS mutation in patients with lung cancer: a predictor for poor prognosis but Not for EGFR-TKIs or chemotherapy. Ann Surg Oncol 4:1381-11388
18. Fukuoka M (2009) Biomarker analyses from a phase III, randomised, open-label, first-line study of gefitinib(G) versus carboplatin/paclitaxel(C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS) J Clin Oncol 27:(suppl 15)
19. Shepherd FA (2005) Erlotinib in previously treated non-small cell lung cancer. N Eng Med 353:123-132
20. Capuzzo F (2010) Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo - controlled phase III study. Lancet Oncol 6:521-529
21. Zhou C, Wu YL (2010) Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line Erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non small cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 21(supp.8):LBA 13
22. Garassino MC (2012) TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild -type (wt) EGFR. J Clin Oncol 30:(abstr LBA7501)
23. Rosell R, Carcereny E et al (2013) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 3:239-246
24. Kim ES, Hirsh V et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST) a randomised phase III trial. The Lancet 372:1809-1818
25. Fukuoka M, Wu Y (2011) Biomarker analyses and final overall survival results from a phase III, randomised, open -label, first-line study of Gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced Non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866-2874
26. Mok TS (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 361:947-957
27. Inoue A, Minegishi M, Maemondo M (2010) Final results of a phase II study of first- line gefitinib for elderly patients (PTS) with advanced non-small cell lung cancer (NSCLC) harbour epidermal growth factor receptor (EGFR) mutations. NEJ 003 study. Ann Oncol 21:(Suppl 8) Abstract:3559
28. The Pirker R, Pereira JR (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 1:33-42
29. Teblutt N, Pedersen MW (2013) Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 13:663-673
30. Miller VA (2012) Phase IIB/III double-blind randomised trial of afatinib (BIBW 2992, an irreversibile inhibitor of EGFR/HER1 and HER2)+best supportive care (BSC) versus placebo+BSC in patients with NSCLC failing 1-2 lines of chemotehrapy and erlotinib or gefitinib (LUX-LUNG 1) Ann Oncol 21:(Suppl 8,LBA1)
31. Chi YJ (2012) LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clinic Oncol 30:18(Suppl. LBA 7500)
32. Pao W (2004) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with second mutation in the EGFR kinase ddomain. PloS Med 2:2129-2139
33. Janjigian YY, Smit EF, Horn L, et al. (2012) Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. Ann Oncol 23:(Suppl 9) abstr. 1227
34. Sequist LV, Besse B (2010) Neratinib, an irreversible Pan-ErB receptor tyrosine kinase inhibitor: result of phase II trial in patients with advanced Non-small-cell lung cancer. J Clin Oncol 18:3076-3083
35. Maemondo M, Inoue A (2010) Gefinitib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Eng J Med 362:2380-2388
36. Pao W, Hutchinson KE (2012) Chipping away the lung cancer genome. Nat Med 18:349.351
37. Yano S, Yamada T (2011) Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in japanase cohort. J Thorac Oncol 6:2011-2017
38. Oxnard GR, Arcila ME (2011) New strategies on overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 17:5530-5537
39. Ohashi K, Maruvka YE (2013) Epidermal growth factor receptor tyrosine kinase inhibitor -resistant disease. J Clin Oncol 31:1070-1080
40. Shikada Y (2005) Platelet-derived growth factor-A is an essential and autocrine regulators of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 6:7241-7248
41. Sandler A (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Eng J Med 24:2542-2550
42. Crino L, Dansin E (2010) Safety and efficacy of first line bevacizumab based in advanced non-squamosus non-small cell lung cancer (SAIL MO19390) Phase 4 study. Lancet Oncol 8:733-740
43. Cho BC, Kim BH, Soo RA (2010) The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced Non-small cell lung cancer the role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced Non-small cell lung cancer. Yonsei Med J 1:1-8
44. Schiller JH, Larson T (2009) Efficacy and safety of axitinib (AG-013736 AG) in patients with advanced Non-small-cell lung cancer: results from phase II study. J Clin Oncol 23:3836-3841
45. Chue QS (2009) Aflibercept(AVE0005) an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2:263-271
46. Goss GD (2010) Randomised, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small cell lung cancer: NCIC clinical trial group BR24 study. J Clin Oncol 1:49-55
47. Wedge SR (2002) ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655
48. Novello S (2009) Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 9:1543-1548
49. Blumenschein GR Jr (2009) Phase II, multicenter, uncontrolled trial of single -agent sorafenib in patients with relapsed or refractory, advanced non -small cell lung cancer. J Clin Oncol 26:4274-4280
50. Polverino A (2006) AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet -derived gowth facror and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 17:8715-8721
51. Blumenschein GR, Kabbinavar F (2011) Randomised open label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamosus non-small cell lung cancer (NSCLC). Ann Oncol 9:2057-2067
52. Aggarwall C (2012) Antiangiogenic agents in the the treatment of non-small cell lung cancer:where do we stand and where are we headed? Cancer Biol Ther 5:247-263
53. Soda M (2007) Identification of the transforming EML4-ALK fusion gene in non -small cell lung cancer. Nature 448:561-567
54. Ardini E, Magnaghi P (2010) Anaplastic lymphoma kinase: role in specifis tumours, and development of small molecule inhibitors for cancer therapy. Cencer letters 299:81-94
55. Capuzzo F, Marchetti A (2009) Increased MET gene copy number negatively affects survival of surgical resected non-small-cell lung cancer patients. J Clin Oncol 27:1667-1674
56. Bergethon K, Shaw AT (2012) ROS1 rearrangements define a unique molecular class of lung cancer. J Clin Oncol 30:863-870
57. McDermott U (2008) Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68:3389-3395
58. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175-180
59. Settleman J (2009) Cell culture modelling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK). Semin Oncol S36-41
60. Kwak EL (2010) Anaplastic lymphoma kinase inhibitions in nonsmall cell lung cancer. N Eng J Med 363:1693-1703
61. Gadgeel M, Bepler G (2011) Crizotinib: an anaplastic lymphoma kinase inhibitor. Future Oncol 8:947-953
62. Alice Tsang S, Ranee Mehra (2013) Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 31:(suppl) Abstr 8010
63. Sequist LV, Akerley Wl (2010) Final results from AR197-209: a global randomised placebo -controlled phase II clinical trial of erlotinib PLUS ARQ197 versus erlotinib plus placebo in previously treated EGFR- inhibitor naive patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 21:(Suppl.8) Abstr 3630
64. Robinson KW, Sandler AB (2013) The role of MET receptor tyrosine kinase in Non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist 18:115-122
65. Herbst RS, Sandler A (2008) Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 13:1166-1176
66. Haisworth J (2008) A phase III multicenter, placebo-controlled, double-blind, randomised clinical trial to evaluate the efficacy of bevacizumab(Avastin) in combination with erlotinib (Tarceva) compared with chemotherapy alone for treatment of advanced non-small cell lung cancer after failure of standard first line chemotherapy. J Thorac Oncol 3:(Suppl.4)
67. Kabbinavar F, Miller VA (2010) Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab(B) therapy with or without erlotinib(E) after completion of chemoterapy with B for first line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol 28:(Suppl 15)abstr 7526
68. Gandara D (2009) S0536: carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced NSCLC: a SWOG phase II study. J Clin Oncol 27:(Suppl.15) abstr 8015
69. Lind JS, Dingemans AMC (2009) A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer. Clin Cancer Res 16:3078-3087
70. Herbst RS, Gordon MS et al. (2013) A study of MPD3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol 31:(suppl) Abstr 3000
71. Dasanu CA, Sethi N (2012) Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol 12:923-937
72. Samuels Y (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554
73. Malaga D (2008) Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell cycle 7:665-669
74. Naoki K (2002) Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62:7001-7003
75. Marks JL (2008) Novel MEK 1 mutation identified by mutational analysis of epidermal growth factor receptor signalling pathway genes in lung adenocarcinoma. Cancer Res 68:5524-5528
76. Gridelli C, Maione P (2008) The potential Role of mTOR inhibitor sin Non-Small-Cell Lung Cancer. Oncologist 2:139-147 (Pubitemid 351342577)
77. Dong S, Zhang XC (2012) Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Chemother Pharmacol 5:707-716
78. Belani CP, Goss G (2011) Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev 38:173-178
79. Frierich MJ (2011) NSCLC drug targets acquire New visibility. J Nat Cancer Inst 5:366